Optimized hGBA1-mRNA Enables Efficient GCase Restoration in GD Models

Study Background and Research Question

Gaucher disease (GD) is a lysosomal storage disorder arising from mutations in the GBA1 gene, which encodes the hydrolase β-glucocerebrosidase (GCase). Deficiency in GCase function leads to pathological accumulation of glucosylceramide (GlcCer) and glucosylsphingosine in macrophages, driving clinical manifestations such as hepatosplenomegaly, anemia, and bone disease. While enzyme replacement therapy (ERT) is the current standard of care, limitations including high cost, frequent infusions, immunogenicity, and inability to cross the blood-brain barrier have prompted the search for more effective and versatile modalities. The reference study addresses whether optimized, lipid nanoparticle (LNP)-delivered human GBA1 mRNA can drive efficient, durable GCase expression and restore lysosomal function in GD models (reference study).

Key Innovation from the Reference Study

The principal innovation lies in the rational design and optimization of human GBA1 mRNA constructs, systematically varying untranslated regions (UTRs), codon usage, and poly(A) tail length to maximize translation efficiency and mRNA stability. Encapsulation in LNPs enabled effective delivery to both cultured cells and animal tissues. Compared to less efficient designs, the best-performing mRNA variant achieved over sixfold higher GCase activity 24 hours post-transfection, with a half-life exceeding 54 hours. Importantly, the mRNA-encoded enzyme localized correctly to lysosomes, restoring normal organelle morphology and reducing substrate accumulation in GBA1-knockout cells (reference study).

Methods and Experimental Design Insights

The study employed a suite of complementary in vitro and in vivo assays to evaluate mRNA construct performance. HEK293T and RAW264.7 cells were transfected with various GBA1 mRNA designs, followed by quantification of GCase enzymatic activity and protein localization using immunocytochemistry. In knockout models, restoration of lysosomal architecture and substrate clearance was assessed. For in vivo validation, LNP-formulated mRNA was administered to wild-type FVB mice, with subsequent measurement of GCase activity in liver and spleen tissues. The enzymatic readouts in both cellular and tissue samples relied on fluorogenic substrates, most notably 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG), which enables sensitive quantification of β-glucocerebrosidase activity via fluorescence emission upon hydrolysis [internal article].

Protocol Parameters

• Cell models: HEK293T and RAW264.7; GBA1-KO lines for functional rescue experiments.
• mRNA optimization: Systematic variation of 5'/3' UTRs, codon usage, and poly(A) tail; selection based on GCase activity and mRNA stability.
• LNP formulation: Standard protocols for mRNA encapsulation; intravenous administration in animal models.
• Enzyme activity assay: Use of 4-MUG fluorogenic substrate; detection of 4-methylumbelliferone fluorescence at emission maxima 445–454 nm.
• Assay conditions: Substrate concentrations typically in the nanomolar to micromolar range depending on sensitivity and background.
• Tissue analysis: GCase activity measured in liver and spleen homogenates 72 h post-injection.

Core Findings and Why They Matter

The optimized hGBA1-mRNA achieved substantially higher GCase expression and enzymatic activity compared to less refined constructs, with activity sustained for over two days in vitro. In GBA1-KO cells, mRNA delivery restored lysosomal morphology and reduced pathologic substrate accumulation, demonstrating functional correction at the cellular level. Following a single systemic administration of hGBA1-mRNA-LNPs in mice, GCase activity was detectable in both liver and spleen, confirming effective in vivo delivery and translation (reference study). These results underscore the feasibility of mRNA-based enzyme restoration, with implications for overcoming key limitations of ERT such as dosing frequency and systemic distribution.

Comparison with Existing Internal Articles

Multiple internal resources contextualize and extend these findings. For example, the article "Optimized hGBA1 mRNA Restores Lysosomal Function in Gaucher Disease" provides additional evidence of mRNA-LNP–mediated GCase expression leading to functional correction in preclinical models, aligning closely with the reference study. The review "4-MUG: Advancing Lysosomal Enzyme Assays for Translational Breakthroughs" discusses how fluorogenic substrates like 4-MUG underpin sensitive, quantitative lysosomal enzyme activity assays crucial for both mechanistic studies and therapeutic evaluation. Further, "4-Methylumbelliferyl-β-D-Glucopyranoside in Lysosomal Enzyme Assays" details the assay chemistry and protocol considerations, supporting the methodological choices of the reference study. Collectively, these articles reinforce the centrality of robust enzyme activity assays in both basic and translational glycosphingolipid metabolism research.

Limitations and Transferability

Despite promising results, the current study is largely preclinical, with efficacy and safety established in cellular and murine models but not yet in human subjects. The biodistribution of LNPs and the immune response to repeated mRNA dosing require further evaluation, particularly regarding potential translation to neuronopathic GD forms where blood-brain barrier penetration is critical. Furthermore, while 4-MUG-based β-glucocerebrosidase activity assays are well validated in vitro and for tissue lysates, translation to clinical biomarker settings may necessitate additional optimization for specificity and sensitivity. Nevertheless, the modular mRNA platform and associated lysosomal enzyme activity assay protocols are likely transferable to other lysosomal storage disorders with similar pathophysiology.

Research Support Resources

For groups aiming to replicate or extend these findings, 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG, SKU C3426) is a widely adopted fluorogenic substrate for quantitative β-glucocerebrosidase and β-glucosidase activity assays. According to the product information, 4-MUG is suitable for cell-based, tissue, and high-throughput screening workflows, with established protocols for solubility and storage at -20°C. Researchers can leverage this tool, available from APExBIO, to support assay development, optimization, and translational research in glycosphingolipid metabolism and lysosomal function.